AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

IMMUTEP LTD

0.046

-0.001-2.13%

Volume:255.97K

Turnover:11.73K

Market Cap:67.79M

PE:-0.85

High:0.047

Open:0.046

Low:0.045

Close:0.047

52wk High:0.470

52wk Low:0.028

Shares:1.47B

Float Shares:1.23B

Volume Ratio:0.21

T/O Rate:0.02%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.054

EPS(LYR):-0.054

ROE:-77.31%

ROA:-42.45%

PB:1.10

PE(LYR):-0.85

Loading ...

Overview Company News Filings

Immutep files beneficial ownership Form 3 for director Elisabeth Amanda Boyce

BUZZ-Australia's Immutep extends gain on FDA orphan drug status for cancer drug

BRIEF-Immutep Ltd Says FDA Granted Orphan Drug Designation For Eftilagimod alfa In Soft Tissue Sarcoma

Immutep wins FDA orphan drug designation for eftilagimod alfa in soft tissue sarcoma

Immutep Ltd - FDA Grants Orphan Drug Designation for Eftilagimod Alfa in Soft Tissue Sarcoma

THOMSON REUTERS

Immutep CEO Marc Voigt files initial beneficial ownership statement

Immutep files Form 3 for COO Deanne Diem Miller initial beneficial ownership statement

Immutep Says JPMorgan Reduces Stake

MT Newswires Live

Immutep director Peter Andrew Meyers files initial beneficial ownership statement

BRIEF-Immutep Discontinues Phase III Tacti-004 Study In Non-Small Cell Lung Cancer

Immutep Ltd - Discontinues Phase Iii Tacti-004 Study in Non-Small Cell Lung Cancer

THOMSON REUTERS

Immutep Ltd - Estimates Review Process Could Extend Into Q3 2026

THOMSON REUTERS

Immutep files initial beneficial ownership statement for Chief Medical Officer Stephan Winckels

Immutep files Form 3 as Chief Development Officer Christian Mueller reports beneficial ownership

ASX Runners of the Week: Immutep, Blue Star Helium & Patagonia

The West Australian

Immutep Says JPMorgan Chase Reduces Stake

MT Newswires Live

Immutep Says Bank of New York Mellon Increases Stake

MT Newswires Live

Rosen Law Firm probes potential securities class action over Immutep disclosures

Immutep Reports Progress From Phase I Study of Lag-3 Agonist for Autoimmune Diseases

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigerfiesta.com/stock/IMM.AU/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"IMM.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"IMM.AU\",,,,,undefined,":{"symbol":"IMM.AU","market":"AU","secType":"STK","nameCN":"IMMUTEP LTD","latestPrice":0.046,"timestamp":1789604211566,"preClose":0.047,"halted":0,"volume":255972,"delay":0,"changeRate":-0.02127659574468087,"nameEN":"IMMUTEP LTD","floatShares":1228247159,"shares":1473721306,"eps":-0.0539,"marketStatus":"Trading","change":-0.001,"latestTime":"09-17 10:20:17 AEST","open":0.046,"high":0.047,"low":0.045,"amount":11726,"amplitude":0.042553,"askPrice":0.046,"askSize":979665,"bidPrice":0.045,"bidSize":2516308,"shortable":3,"etf":0,"ttmEps":-0.0539,"tradingStatus":2,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1789624800000},"marketStatusCode":2,"adr":0,"exchange":"ASX","adjPreClose":0.047,"openAndCloseTimeList":[[1789603200000,1789624800000]],"volumeRatio":0.205353,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"IMM.AU","preClose":0.047,"auctionPrice":0.046,"auctionVolume":180994,"auctionTime":1789603145666,"referenceTime":1789554603098,"auction":1,"marketStatus":"盘前竞价","timestamp":1789603145666}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"IMM.AU\",,,,,undefined,":{"symbol":"IMM.AU","floatShares":1228247159,"roa":"-42.45%","roe":"-77.31%","lyrEps":-0.0539,"volumeRatio":0.205353,"shares":1473721306,"dividePrice":0,"high":0.047,"amplitude":0.042553,"preClose":0.047,"low":0.045,"week52Low":0.028,"pbRate":"1.10","psRate":"3.40","week52High":0.47,"institutionHeld":0,"latestPrice":0.046,"committee":0.439547,"eps":-0.0539,"divideRate":0,"volume":255972,"delay":0,"ttmEps":-0.0539,"open":0.046,"prevYearClose":0.415,"prevWeekClose":0.056,"prevMonthClose":0.048,"prevQuarterClose":0.053,"fiveDayClose":0.044,"twentyDayClose":0.054,"sixtyDayClose":0.051,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IMM.AU\",params:#limit:5,,,undefined,":[{"market":"AU","date":"2024-06-05","symbol":"IMM.AU","defaultRemindTime":1717545600000,"type":"split","dateTimestamp":1717509600000,"forFactor":948148,"toFactor":1000000,"ratio":0.9481480000000001}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IMM.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IMM.AU\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2627299905","title":"Immutep files beneficial ownership Form 3 for director Elisabeth Amanda Boyce","url":"https://stock-news.laohu8.com/highlight/detail?id=2627299905","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627299905?lang=en_us&edition=fundamental","pubTime":"2026-04-16 18:06","pubTimestamp":1776334014,"startTime":"0","endTime":"0","summary":"Immutep director Elisabeth Amanda Boyce filed an initial U.S. SEC Form 3 reporting 423,288 ordinary shares held directly as of March 18, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immutep Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 16, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260416:nNDL5J4M9T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","IMM.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627257758","title":"BUZZ-Australia's Immutep extends gain on FDA orphan drug status for cancer drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2627257758","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627257758?lang=en_us&edition=fundamental","pubTime":"2026-04-16 10:24","pubTimestamp":1776306262,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Immutep extends gain on FDA orphan drug status for cancer drug** Shares of Australian biotechnology firm Immutep IMM.AX rise as much as 22.2% to A$0.075, their highest since March 6**","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260416:nL4N40Z06C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMM.AU","BK7067","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627476113","title":"BRIEF-Immutep Ltd Says FDA Granted Orphan Drug Designation For Eftilagimod alfa In Soft Tissue Sarcoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2627476113","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627476113?lang=en_us&edition=fundamental","pubTime":"2026-04-15 09:21","pubTimestamp":1776216119,"startTime":"0","endTime":"0","summary":"BRIEF-Immutep Ltd Says FDA Granted Orphan Drug Designation For Eftilagimod alfa In Soft Tissue SarcomaApril 15 (Reuters) - Immutep Ltd IMM.AX:IMMUTEP LTD - FDA GRANTS ORPHAN DRUG DESIGNATION FOR EFTILAGIMOD ALFA IN SOFT TISSUE SARCOMASource text: ID:nASX4fL5nrFurther company coverage: IMM.AX","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260415:nFWN40X171:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","IMM.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627753974","title":"Immutep wins FDA orphan drug designation for eftilagimod alfa in soft tissue sarcoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2627753974","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627753974?lang=en_us&edition=fundamental","pubTime":"2026-04-15 08:41","pubTimestamp":1776213697,"startTime":"0","endTime":"0","summary":"Designation supports potential late-stage development in resectable disease following Phase II EFTISARC-NEO results.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immutep Ltd. published the original content used to generate this news brief on April 15, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260415:nNDL9NDDby:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","IMM.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627207654","title":"Immutep Ltd - FDA Grants Orphan Drug Designation for Eftilagimod Alfa in Soft Tissue Sarcoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2627207654","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627207654?lang=en_us&edition=fundamental","pubTime":"2026-04-15 07:27","pubTimestamp":1776209236,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260414:nFWN40X171:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","IMM.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627984244","title":"Immutep CEO Marc Voigt files initial beneficial ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2627984244","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627984244?lang=en_us&edition=fundamental","pubTime":"2026-04-14 09:58","pubTimestamp":1776131907,"startTime":"0","endTime":"0","summary":"Immutep CEO, CFO, executive director Marc Voigt filed an initial Form 3 showing 14,792,145 ordinary shares held.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immutep Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 13, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260414:nNDL9blLH5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","IMM.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627343124","title":"Immutep files Form 3 for COO Deanne Diem Miller initial beneficial ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2627343124","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627343124?lang=en_us&edition=fundamental","pubTime":"2026-04-13 18:22","pubTimestamp":1776075725,"startTime":"0","endTime":"0","summary":"Immutep COO Deanne Diem Miller filed an initial beneficial ownership statement reporting 2,867,305 ordinary shares.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immutep Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 13, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260413:nNDLbgXFYR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMM.AU","BK7508","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627487792","title":"Immutep Says JPMorgan Reduces Stake","url":"https://stock-news.laohu8.com/highlight/detail?id=2627487792","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627487792?lang=en_us&edition=fundamental","pubTime":"2026-04-13 15:25","pubTimestamp":1776065154,"startTime":"0","endTime":"0","summary":"Immutep (ASX:IMM) said JPMorgan and its affiliates have reduced their stake in the company on April 8 to 6.94% or 102.3 million shares from 8.28% or 122.0 million shares, according to a Monday Australian bourse filing.The company's shares were down 10% on market close.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU2552382215.SGD","LU0345769128.USD","LU0820562030.AUD","LU0320765489.SGD","LU0070302665.USD","LU0882574139.USD","JPMO","LU0203345920.USD","LU1720051108.HKD","IMM.AU","JPO","LU2237443978.SGD","LU1629891620.HKD","LU2213496289.HKD","LU2746668461.USD","LU1894683348.USD","LU2242649171.HKD","LU1974910355.USD","LU0048584097.USD","LU2756315318.SGD","LU0976567544.SGD","LU1084165304.USD","LU2054465674.USD","IE00BJTD4N35.SGD","LU0211326755.USD","IE00BLSP4452.SGD","LU0106261372.USD","LU0267386448.USD","LU0265550359.USD","LU0640476718.USD","JPM","LU2746668974.SGD","LU0942090050.USD","BK4534","LU1145028129.USD","IE00BHPRN162.USD","SG9999002224.SGD","LU0006306889.USD","LU1116320901.HKD","LU2023250504.SGD","IE000M9KFDE8.USD","LU2417539215.USD","IE00BKVL7J92.USD","IE00BYXW3230.USD","LU2430703178.SGD","LU1162221912.USD","LU0310799852.SGD","SG9999002232.USD","LU2023250330.USD","LU0820561909.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625399389","title":"Immutep director Peter Andrew Meyers files initial beneficial ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2625399389","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625399389?lang=en_us&edition=fundamental","pubTime":"2026-04-08 09:29","pubTimestamp":1775611793,"startTime":"0","endTime":"0","summary":"Immutep director Peter Andrew Meyers filed an initial beneficial ownership statement showing 4,052,173 ordinary shares held directly as of March 18, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immutep Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 07, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260408:nNDL5CrYXc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","BK7508","IMM.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625998707","title":"BRIEF-Immutep Discontinues Phase III Tacti-004 Study In Non-Small Cell Lung Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2625998707","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625998707?lang=en_us&edition=fundamental","pubTime":"2026-04-08 09:24","pubTimestamp":1775611490,"startTime":"0","endTime":"0","summary":"BRIEF-Immutep Discontinues Phase III Tacti-004 Study In Non-Small Cell Lung CancerApril 8 (Reuters) - Immutep Ltd IMM.AX:DISCONTINUES PHASE III TACTI-004 STUDY IN NON-SMALL CELL LUNG CANCERESTIMATES R","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260408:nFWN40Q17Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7067","IMM.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625996751","title":"Immutep Ltd - Discontinues Phase Iii Tacti-004 Study in Non-Small Cell Lung Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2625996751","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625996751?lang=en_us&edition=fundamental","pubTime":"2026-04-08 08:06","pubTimestamp":1775606815,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260408:nFWN40Q17Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","BK7508","IMM.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625675489","title":"Immutep Ltd - Estimates Review Process Could Extend Into Q3 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2625675489","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625675489?lang=en_us&edition=fundamental","pubTime":"2026-04-08 08:06","pubTimestamp":1775606815,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260408:nFWN40Q17Z:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","IMM.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624594703","title":"Immutep files initial beneficial ownership statement for Chief Medical Officer Stephan Winckels","url":"https://stock-news.laohu8.com/highlight/detail?id=2624594703","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624594703?lang=en_us&edition=fundamental","pubTime":"2026-04-01 18:21","pubTimestamp":1775038871,"startTime":"0","endTime":"0","summary":"Immutep initial Form 3 showed Chief Medical Officer Stephan Karel Gerard Winckels held 92,935 ordinary shares as of March 18, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immutep Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 01, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260401:nNDL3jK9sr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","IMM.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624594974","title":"Immutep files Form 3 as Chief Development Officer Christian Mueller reports beneficial ownership","url":"https://stock-news.laohu8.com/highlight/detail?id=2624594974","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624594974?lang=en_us&edition=fundamental","pubTime":"2026-04-01 18:11","pubTimestamp":1775038296,"startTime":"0","endTime":"0","summary":"Immutep Chief Development Officer Christian Mueller reported direct ownership of 3.77 million ordinary shares in an initial Form 3 filing dated 03/18/2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immutep Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 01, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260401:nNDL2YGvfv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","IMM.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620077912","title":"ASX Runners of the Week: Immutep, Blue Star Helium & Patagonia","url":"https://stock-news.laohu8.com/highlight/detail?id=2620077912","media":"The West Australian","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620077912?lang=en_us&edition=fundamental","pubTime":"2026-03-20 06:10","pubTimestamp":1773958210,"startTime":"0","endTime":"0","summary":"The Bulls N’ Bears ASX Runner of the Week is… Immutep. In a slightly perverse twist, the oncology mid-cap bounced hard from last week’s 90 per cent drop, gaining 53 per cent after a brutal sell-off. ","market":"nz","thumbnail":"https://images.thewest.com.au/publication/C-22008191/f3ba145e5bde0aa97d4b38a2ae55d7e52f82c4d9.jpg","type":0,"news_type":0,"thumbnails":["https://images.thewest.com.au/publication/C-22008191/f3ba145e5bde0aa97d4b38a2ae55d7e52f82c4d9.jpg"],"rights":{"source":"thewest_stock","url":"https://thewest.com.au/business/bulls-n-bears/asx-runners-of-the-week-immutep-blue-star-helium-patagonia--c-22008191","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://thewest.com.au/business/bulls-n-bears/asx-runners-of-the-week-immutep-blue-star-helium-patagonia--c-22008191","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"thewest_stock","symbols":["BNL.AU","BK7508","BK4588","BK7095","DUG","XOP","IMM.AU","PL3.AU","BK4570","BK7142","BK7067","BK4585"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2620638274","title":"Immutep Says JPMorgan Chase Reduces Stake","url":"https://stock-news.laohu8.com/highlight/detail?id=2620638274","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620638274?lang=en_us&edition=fundamental","pubTime":"2026-03-20 05:44","pubTimestamp":1773956688,"startTime":"0","endTime":"0","summary":"Immutep (ASX:IMM) received notice that JPMorgan Chase and its affiliates decreased their holdings in the company to 5.83% from 7.49%, according to a Friday filing with the Australian bourse.JPMorgan Chase and its affiliates now own 85.9 million shares in the company, the filing said.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0203345920.USD","LU2505996509.AUD","IMM.AU","IE00BDCRKT87.USD","JPM","LU2746668461.USD","JPMO","IE00B775SV38.USD","LU1267930490.SGD","LU2054465674.USD","LU0048584097.USD","IE0034235188.USD","IE0034235295.USD","LU0265550946.USD","LU0323591593.USD","LU1720051017.SGD","LU1084165304.USD","IE00BZ1G4Q59.USD","LU2237443622.USD","LU0417517546.SGD","LU0345770308.USD","LU0942090050.USD","IE000M9KFDE8.USD","LU0496365809.HKD","LU1670628061.USD","IE00BN8TJ469.HKD","LU2237443978.SGD","IE0034235303.USD","LU2552382215.SGD","IE00B1XK9C88.USD","LU0006306889.USD","LU0310799852.SGD","BK7067","LU0345769128.USD","LU0640476718.USD","LU0211331839.USD","LU2381873111.SGD","LU0170899867.USD","LU1894683264.USD","BK4585","IE00BBT3K403.USD","BK7508","LU0211328371.USD","LU1988902786.USD","LU2237443895.HKD","LU1145028129.USD","IE00BJTD4V19.USD","LU1032466523.USD","LU2505996681.GBP","SG9999002232.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620746812","title":"Immutep Says Bank of New York Mellon Increases Stake","url":"https://stock-news.laohu8.com/highlight/detail?id=2620746812","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620746812?lang=en_us&edition=fundamental","pubTime":"2026-03-20 05:44","pubTimestamp":1773956658,"startTime":"0","endTime":"0","summary":"Immutep  received notice that Bank of New York Mellon and its affiliated entities increased their holdings in the company to 20.08% from 19.04%, according to a Friday filing with the Australian bourse.Bank of New York Mellon and its affiliates now own about 296 million shares in the company, the filing said.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4559","BK7508","BK4588","LU0130102774.USD","BK4135","LU0980610538.SGD","LU1699723380.USD","LU0130517989.USD","LU0648001328.SGD","BK","BK7067","IMM.AU","LU0477156953.USD","BK4585","LU1201861249.SGD","LU1571399168.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620275803","title":"Rosen Law Firm probes potential securities class action over Immutep disclosures","url":"https://stock-news.laohu8.com/highlight/detail?id=2620275803","media":"Reuters","labels":["policyRegulatory","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620275803?lang=en_us&edition=fundamental","pubTime":"2026-03-20 03:07","pubTimestamp":1773947236,"startTime":"0","endTime":"0","summary":"Rosen Law Firm said it is investigating potential securities claims on behalf of Immutep shareholders over allegations of materially misleading business information.The investigation follows Immutep’s announcement that an independent data monitoring committee recommended discontinuing the TACTI-004 Phase III trial of eftilagimod alfa in first-line non-small cell lung cancer after an interim futility analysis.After the announcement, Immutep’s ADR fell $2.28 to $0.48, a decline of 82.6%.The firm said it is preparing a securities class action seeking recovery of investor losses.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nNDLbqrQ9p:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0314104364.USD","BK4588","BK4112","IMM.AU","IE00B64PRP62.GBP","SG9999014013.SGD","LU2210150020.SGD","IE00BKPKM429.USD","LU2095319765.USD","IE00BN0W2W23.USD","IE00BN0W2T93.GBP","LU2210149790.SGD","IE00BGHQF748.EUR","SG9999014039.USD","BK7067","BK7508","SG9999014005.SGD","IE00BN0W2V16.EUR","NDAQ","SG9999014021.USD","IE00B3QW5Z07.USD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620247976","title":"Immutep Reports Progress From Phase I Study of Lag-3 Agonist for  Autoimmune Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2620247976","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620247976?lang=en_us&edition=fundamental","pubTime":"2026-03-19 20:00","pubTimestamp":1773921604,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nTUA4SLSWY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","BK7508","IMM.AU"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":3,"totalSize":59,"code":"91000000","status":"200"}]}}